Within the CMCR, there is also “much interest in the possible anti-inflammatory effects of CBD, for use in arthritis of various types, including knees and hands,” Atkinson said. Recent in vitro research with human cell lines afflicted with rheumatoid arthritis has suggested that CBD treatment may help reduce inflammation.
CBD, short for cannabidiol, is a trending ingredient the natural products industry and is the focus of a new area of cannabis research. CBD is one of many cannabinoids, or molecules produced uniquely by the cannabis family. Unlike tetrahydrocannabinol (THC, the primary psychoactive element in marijuana), CBD is non-psychoactive, meaning it doesn’t have a strong effect on cognitive brain activity and doesn’t cause the “high” associated with marijuana.
Scientific observation takes time, and the research community has only just begun to pursue scientific inquiry into the discrete effects of various cannabinoids. That said, many researchers believe the potential carried by CBD is promising.
Research on CBD
Atkinson emphasized that “CBD, like many other substances, probably should be avoided in pregnancy.” Additionally, since the commercial cannabis market is mostly unregulated, there is no good way to know that what you buy is actually what you get in terms of dosage or content of product. “In studies done by the state of California it appears that a good deal of product labeling is incorrect — the dose or percentage of CBD or THC is usually overstated,” he said.
A 2017 clinical trial published in The New England Journal of Medicine found that CBD was highly effective in reducing seizures in people with Dravet syndrome, a rare form of epilepsy. The FDA subsequently approved an oral CBD solution, called Epidiolex, for treating the rare disease.
Every variety of the cannabis family produces cannabinoids, including hemp. While CBD and THC are the most well-known cannabinoids, there are many different types, and only recently have significant resources been poured into their study. Our brains have specific receptors designed to accept cannabinoids, known as CB1 and CB2. These receptors are responsible for the assimilation of cannabinoid molecules into your system, resulting in the psychoactive and immune responses correlated with cannabis consumption.
Some research suggests that CBD may reduce anxiety and self-deprecating thoughts, and there’s evidence that CBD has antipsychotic effects in people with schizophrenia. But other studies show no significant benefit of CBD over a placebo.
If you’re using CBD, it’s a good idea to do some research to inform your dosage . Young children can tolerate daily doses of up to 20 milligrams per kilogram of body weight . For a 175-pound (79.4-kilogram) adult, that’s more than 1,500 milligrams. The most common side effect of large doses of CBD is sleepiness.
CBD fits the definition of a psychoactive substance as it can subtly alter perception and mood. However, it’s important to reiterate that unlike weed, CBD does not cause intoxication. CBD is a non-intoxicating substance, so it cannot stimulate the level of sensory and psychological effects that THC does.
Is CBD a drug?
Also, CBD derived from industrial hemp lacks the incredibly diverse profile of different cannabinoids and terpenes found in whole-plant marijuana. CBD derived from hemp seems to have a weaker entourage effect.
Research into CBD has been conducted for the following conditions.
The scientists behind this study noticed that researchers had been utilizing pure, single-molecule CBD, which resulted in a bell-shaped dose-response curve. This curve indicates that CBD’s efficacy plummets at very high and very low doses.
Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects. Molecules. 2019;24(16). pii: E2967. View abstract.
Consroe P, Wolkin A. Cannabidiol-antiepilpetic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977;201(1):26-32. View abstract.
Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94. View abstract.
Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012;18(2):219-28. View abstract.
Bornheim LM, Everhart ET, Li J, Correia MA. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 1993;45(6):1323-31. View abstract.
Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos 1988;16(3):469-72. View abstract.
Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex), as add-on therapy, in subjects with refractory spasticity cause by multiple sclerosis. Eur J Neurol 2011;18(9):1122-31. View abstract.